Our results showed a variable amount of HER2 ECD in the serum with the concentration ranging from 71.9 to above 210 ng/ml in the patient with breast cancer showing low expression of HER2 (1+), which is considered HER2 negative tumor (Table 4). Here, ERBB2 is linked to breast cancer.